Pfizer Paxlovid

• U.S. FDA orders Pfizer to test 2nd Paxlovid course for rebound COVID patients

  The U.S. FDA has ordered Pfizer Inc PFE.N to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment

  Health

  Aug 19, 2022
  
• U.S. doctors reconsider use of Pfizer’s COVID-19 pill for lower-risk patients

  Paxlovid's emergency authorization stipulates that it should be used only for newly infected people with risk factors, but doctors said many others have sought out a prescription.

  Health

  May 28, 2022
  
• Advertisement
• Generic versions of Pfizer’s Paxlovid to be sold in low-income countries for $25 or less

  A generic course of molnupiravir is expected to cost about $20 in poorer nations, compared with the roughly $700 per course Merck is charging the United States.

  Health

  May 12, 2022
• Advertisement
• Some report COVID symptoms after taking Pfizer’s Paxlovid. Here’s what we know

  As Paxlovid has become more widely used, some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement.

  Health

  May 11, 2022
• Paxlovid ‘inaccessible’ to many patients in Canada. Here’s why that needs to change

  With COVID-19 infections surging across Canada, experts say the patchwork distribution system for Paxlovid throughout the country may inhibit those who most need the drug.

  Canada

  Apr 13, 2022